On December 10^th , 2015, Everpine Capital completed the first phase of its investment in Eye Tech Care (ETC) of France, becoming ETC's largest shareholder and focusing on helping ETC expand in the Chinese market.

ETC, a French high-tech medical device company, is one of the world's most advanced non-invasive focused ultrasound glaucoma treatment technologies provider and has received European CE certification, treating more than 5,000 patients worldwide. It is safe, fast and effective, and has been highly recognized by the global glaucoma industry, including the president of the glaucoma association of many countries.

Glaucoma is a serious eye disease that causes optic disc depression and visual field defect due to increased intraocular pressure. China has the largest number of glaucoma patients in the world, accounting for a quarter of the nearly 80 million glaucoma patients worldwide. There is no ideal treatment for glaucoma at present, ETC's products are expected to provide a revolutionary solution for the treatment of glaucoma.

Dr. Tao Wu, the managing partner who is responsible for the healthcare field in Everpine Capital dominated the investment in the ETC. Dr Tao Wu graduating from the Mayo Clinic with Ph.D. degree in biomedical science, has rich experience in medical industry and management experience of large companies He was former chairman of the board in GE medical and president of a large domestic private industrial group. He managed two listed companies. According to Dr. Tao Wu, advanced medical technology and products are the key components in the 8 trillion RMB potential health market China. At present, there is still a gap between domestic medical technology and international advanced level, and many advanced technologies and products in many fields are occupied by some foreign companies.